DUOS-publicaties 2022

We hebben er al eerder aandacht aan besteed: wat bereikte DUOS het afgelopen jaar? Wat waren de ontwikkelingen?  En de hoogtepunten? 

Tot de output behoren zeker ook publicaties die verschenen naar aanleiding van DUOS studies. Zonder volledig te zijn, hierbij een kort overzicht van artikelen die verschenen in toonaangevende internationale magazines.

1. Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8⁺ T cells

2 Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands

3. Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD

4. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

5. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma

6. Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

7, Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

8 Influence of Darolutamide on Cabazitaxel Systemic Exposure

9. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients

10. Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer

11 Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

12 A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

13 Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up☆